Companies › Mabsoft Therapeutics (Shanghai)
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology, Immunology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MST-931 monoclonal antibody | – | Phase 1 | Ankylosing Spondylitis (AS) | Jul 2027 |
| MST-168 Antibody-drug conjugate (ADC) | – | Phase 1 | Neoplams | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07903493 | MST-931 | Phase 1 | Ankylosing Spondylitis (AS) | Immunology | Jul 2027 |
| NCT07644650 | MST-168 | Phase 1 | Neoplams | Oncology | Jun 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.